Switching from Depakote to Lithium in a 67-Year-Old Man
Begin lithium at 150 mg nightly while maintaining current Depakote doses initially, obtain baseline labs (renal function, thyroid, electrolytes, CBC, ECG), then gradually taper Depakote by 250 mg every 1-2 weeks over 4-6 weeks while titrating lithium to therapeutic levels (0.6-0.8 mEq/L), with close monitoring for mood destabilization. 1
Critical Baseline Requirements Before Starting Lithium
Before initiating lithium, you must obtain:
- Renal function: BUN, creatinine, urinalysis 2
- Thyroid function tests (TSH, free T4) 2
- Complete blood count 2
- Serum calcium 2
- ECG (given age 67 and cardiac risk with multiple medications) 3
- Pregnancy test if applicable (not relevant here)
Critical consideration: At age 67, this patient has reduced capacity to eliminate both valproate and lithium compared to younger adults 4. Start with lower lithium doses and increase more slowly with regular monitoring for fluid/nutritional intake, dehydration, and somnolence 4.
Cross-Titration Protocol
Week 1-2: Initiation Phase
- START: Lithium 150 mg nightly with food (as planned)
- CONTINUE: All current Depakote doses unchanged (500 mg x2 at bedtime + 250 mg ER at bedtime = 1250 mg total daily)
- CONTINUE: Seroquel XR 600 mg nightly
- TAPER: Prozac 20 mg to 10 mg for one week, then STOP (as planned - appropriate given antidepressants should be discontinued or minimized in bipolar disorder unless combined with mood stabilizer) 1
Rationale: Maintain mood stability during transition by keeping full Depakote coverage while establishing lithium 1. The WHO guidelines emphasize that lithium should only be initiated where close clinical and laboratory monitoring are available 1.
Week 2-3: Lithium Titration
- Increase lithium to 300 mg nightly (or 150 mg BID if tolerated better)
- Check lithium level 5 days after dose change (12 hours post-dose)
- Target therapeutic range: 0.6-0.8 mEq/L (lower end for elderly patients) 5
- CONTINUE: Full Depakote dose
- Monitor for lithium side effects: tremor, polyuria, polydipsia, GI upset, cognitive dulling
Week 3-4: Begin Depakote Taper
Once lithium level reaches 0.4-0.6 mEq/L:
- Reduce Depakote ER 250 mg - DISCONTINUE this dose first
- Continue Depakote 500 mg x2 at bedtime (1000 mg total)
- Continue titrating lithium as needed based on levels
Week 5-6: Continue Depakote Taper
- Reduce Depakote to 500 mg once nightly (eliminate one 500 mg dose)
- Continue lithium at therapeutic dose
- Check lithium level weekly during this transition
Week 7-8: Final Depakote Taper
- Reduce Depakote to 250 mg nightly
- Maintain therapeutic lithium levels
Week 9-10: Complete Transition
- DISCONTINUE final Depakote dose
- Maintain lithium at therapeutic level (0.6-0.8 mEq/L for elderly)
Critical warning: Abrupt discontinuation of Depakote risks mood destabilization and breakthrough mania 4. The gradual taper over 4-6 weeks minimizes this risk while establishing lithium coverage.
Monitoring Schedule
During Cross-Titration (Weeks 1-10):
- Lithium levels: Weekly until stable, then every 2 weeks 2
- Renal function and electrolytes: Every 2-4 weeks
- Mood symptoms: Weekly assessment for breakthrough mania or depression
- Side effects: Monitor for lithium toxicity (tremor, confusion, ataxia, polyuria)
After Stabilization:
- Lithium levels: Every 3-6 months 2
- Thyroid function: Every 3-6 months 2
- Renal function: Every 3-6 months 2
- Urinalysis: Every 3-6 months 2
Management of Concurrent Medications
Seroquel XR 600 mg nightly - CONTINUE
- Provides additional mood stabilization and helps with sleep
- Second-generation antipsychotics are first-line for bipolar disorder 1, 6
- Monitor for metabolic effects (weight, glucose, lipids) 2
Prozac 10 mg then STOP - APPROPRIATE
- Antidepressants in bipolar disorder should always be combined with mood stabilizer and minimized when possible 1
- SSRIs can destabilize mood and trigger mania 2
- Tapering over one week at 10 mg is reasonable for fluoxetine given its long half-life 5
Ambien CR 12.5 mg PRN - CONTINUE with CAUTION
- High-risk medication in elderly per Beers criteria 7
- Consider gradual taper once mood is stable
- Increased fall risk, especially combined with Seroquel 7
- Alternative: optimize sleep hygiene, consider trazodone if needed
Hydroxyzine 25 mg BID PRN - CONTINUE
- Relatively safe anxiolytic option
- Preferable to benzodiazepines in elderly 5
Critical Safety Considerations
Age-Related Concerns (67 years old):
- Reduced drug clearance for both lithium and valproate 4
- Higher somnolence risk with valproate in elderly 4
- Increased sensitivity to lithium neurotoxicity 5
- Dehydration risk: Monitor fluid intake closely 4
Drug Interactions:
- Quetiapine + lithium: Monitor for increased sedation and orthostatic hypotension
- NSAIDs: Avoid if possible (increase lithium levels and nephrotoxicity risk)
- Thiazide diuretics: Increase lithium levels significantly
- ACE inhibitors/ARBs: Increase lithium levels
Warning Signs Requiring Immediate Attention:
- Lithium toxicity: Coarse tremor, confusion, ataxia, slurred speech, nausea/vomiting
- Breakthrough mania: Decreased sleep, increased energy, impulsivity
- Breakthrough depression: Worsening mood, suicidal ideation
- Cardiac symptoms: Given age and QTc concerns with multiple psychotropics 3
Rationale for This Approach
Why cross-titration rather than direct switch: Abrupt mood stabilizer discontinuation risks destabilization 1. Maintaining Depakote coverage while establishing lithium provides continuous mood protection.
Why lithium over continuing Depakote: Lithium demonstrates superior long-term prophylactic efficacy compared to valproate 8, 9, with neuroprotective effects and reduced dementia risk 10. Valproate shows increased dementia risk in some studies 10 and has concerning metabolic and cognitive effects in elderly patients 4.
Why slow taper: Elderly patients require more gradual medication changes due to altered pharmacokinetics and increased sensitivity to withdrawal effects 7, 11, 4.